Pfizer culls RSV treatment from ReViral acquisition
Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 million acquisition of ReViral in 2022. The New York drug company — which is...
View ArticleClik here to view.
GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST 2024 Annual Meeting. In the Phase 3 trial, called AReSVi-006, a dose of...
View ArticlePfizer details results from failed Phase 3 trial of Duchenne muscular...
The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant functional benefit one year after receiving the therapy despite the...
View ArticleClik here to view.
GSK touts data from two late-stage trials with long-acting drug in chronic...
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this time in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Both...
View ArticleTPG and Blackstone working on bid to buy eye care company Bausch + Lomb — report
Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + Lomb, the Financial Times reports. Citing “people familiar with the matter,”...
View ArticleEli Lilly reveals £279M investment in the UK through new government deal
Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring its Gateway Labs overseas for the first time. The...
View ArticleNovartis used a PRV to speed Kisqali's latest indication, FDA says
Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, the FDA said Monday. The FDA did not disclose where this PRV came to Novartis...
View ArticleNovo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days
Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo Nordisk and Eli Lilly have launched legal campaigns against medical spas,...
View ArticleClik here to view.
Forbion raises €2.1B for two new biotech funds after series of company exits
Dutch biotech investor Forbion has raised two new funds to put into biotech companies, just 18 months after its last major raise and following a series of successful exits in its portfolio. The new...
View ArticleBiotech tools company Nuclera raises $75M for protein manufacturing tech
Protein production company Nuclera has raised a $75 million Series C to continue to bring its manufacturing platform to market next January after a soft launch in May. “This is a perfect time to start...
View ArticleClik here to view.
Seraxis gets green light for stem cell-derived therapy for diabetes, aiming...
Stem cell biologist William Rust has been quietly working on a cure for diabetes for more than a decade. Later this year, surgeons will implant his company’s pancreatic organoids in people with type 1...
View ArticleTolerance Bio emerges from stealth with $17.2M to advance therapies developed...
Tolerance Bio has launched with an oversubscribed $17.2 million seed round and a goal to develop therapies for immune-mediated diseases, from cancer to transplant rejection, using the thymus. The...
View ArticlePfizer partners with molecular glue startup Triana Biomedicines in $49M...
Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working in the trendy field of molecular glues. The companies will work on multiple...
View ArticleClik here to view.
Walgreens plans to close 1,200 pharmacies
Walgreens is closing 1,200 stores, or 14% of its locations, as it fights to turn around its business. The retail pharmacy chain will be closing the stores over the next three years, the company said in...
View ArticleMeiraGTx's stock rises on small Parkinson's gene therapy dataset
MeiraGTx unveiled results from a small dataset for its Parkinson’s disease gene therapy on Tuesday morning, causing its shares $MGTX to jump by as much as 24%. In what the company called a “bridging...
View ArticleCycle makes another offer for Vanda; Ocean Biomedical, Molecure ink new deal
Plus, news about Gilead Sciences and Yuhan: Vanda gets second unsolicited offer: Cycle Group Holdings again submitted a proposal to buy Vanda for $8 per share in cash. Vanda, which is currently trading...
View ArticleJ&J trims pipeline, including two mid-stage neuroscience studies
Johnson & Johnson cut a handful of trials across its portfolio in the third quarter, including a Phase 2 study of a touted neuroscience treatment. Missing in the company’s updated pipeline list is...
View ArticleClik here to view.
First patient who received engineered B cell therapy sees early promise for...
Immusoft gave a glimpse on Monday at how the first patient to ever receive an engineered B cell therapy is doing nine months after being dosed, suggesting that the treatment has been safe so far and is...
View ArticleClik here to view.
J&J’s medtech slump continues, improvements not expected until 2025
Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the...
View ArticleClik here to view.
Jazz reports Phase 3 success for Zepzelca in first-line maintenance for small...
Jazz Pharmaceuticals announced Tuesday that adding its small cell lung cancer drug Zepzelca to a maintenance treatment regimen for extensive-stage small cell lung cancer cut the risk of death in a...
View Article